NO950030L - Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose - Google Patents

Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose

Info

Publication number: NO950030L
Authority: NO; Norway
Prior art keywords: ring; toxoplasmosis; treatment; infection; spiropiperidyl
Prior art date: 1993-05-05

Application number

NO950030A

Other languages

English (en)

Norwegian (no)

Other versions

NO950030D0 (no

Inventor

Jack S Remington

Fausto G Araujo

Original Assignee

Palo Alto Medical Found

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-05

Filing date

1995-01-04

Publication date

1995-01-04

1994-02-28 Priority claimed from US08/203,539 external-priority patent/US5529994A/en

1995-01-04 Application filed by Palo Alto Medical Found filed Critical Palo Alto Medical Found

1995-01-04 Publication of NO950030D0 publication Critical patent/NO950030D0/no

1995-01-04 Publication of NO950030L publication Critical patent/NO950030L/no

Links

201000005485 Toxoplasmosis Diseases 0.000 title abstract 2
HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical class OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 title abstract 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
208000015181 infectious disease Diseases 0.000 abstract 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
229910052799 carbon Inorganic materials 0.000 abstract 2
125000004122 cyclic group Chemical group 0.000 abstract 2
125000002883 imidazolyl group Chemical group 0.000 abstract 2
BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical class O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 abstract 1
241000223997 Toxoplasma gondii Species 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000003386 piperidinyl group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicinal Preparation (AREA)

NO950030A 1993-05-05 1995-01-04 Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose NO950030L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US5728893A	1993-05-05	1993-05-05
US08/203,539 US5529994A (en)	1993-05-05	1994-02-28	Treatment for toxoplasmosis
PCT/US1994/004765 WO1994025038A1 (en)	1993-05-05	1994-04-29	Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis

Publications (2)

Publication Number	Publication Date
NO950030D0 NO950030D0 (no)	1995-01-04
NO950030L true NO950030L (no)	1995-01-04

Family

ID=26736295

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO950030A NO950030L (no)	1993-05-05	1995-01-04	Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose

Country Status (14)

Country	Link
US (5)	US5670496A (de)
EP (1)	EP0648121B1 (de)
JP (1)	JPH07509003A (de)
AT (1)	ATE143601T1 (de)
AU (1)	AU669300B2 (de)
CA (1)	CA2138643A1 (de)
DE (1)	DE69400631T2 (de)
DK (1)	DK0648121T3 (de)
ES (1)	ES2095772T3 (de)
GR (1)	GR3021828T3 (de)
IL (1)	IL109543A (de)
NO (1)	NO950030L (de)
RU (1)	RU2121838C1 (de)
WO (1)	WO1994025038A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9224739D0 (en) *	1992-11-26	1993-01-13	Wellcome Found	Medicaments
GB9424013D0 (en) *	1994-11-29	1995-01-18	Wellcome Found	Medicaments
US6258532B1 (en)	1997-08-14	2001-07-10	Vanderbilt University	Methods for in vitro susceptibility testing of chlamydia
US6710033B1 (en)	1996-08-14	2004-03-23	Vanderbilt University	Methods and treatment of multiple sclerosis
US6579854B1 (en)	1996-08-14	2003-06-17	Vanderbilt University	Diagnosis and management of infection caused by chlamydia
US6890526B2 (en) *	1997-05-06	2005-05-10	Vanderbilt University	Methods and reagents for the treatment of multiple sclerosis
AU3760400A (en) *	1999-03-19	2000-10-09	Vanderbilt University	Methods and reagents for the diagnosis and treatment of multiple sclerosis
US7074832B2 (en)	2001-09-24	2006-07-11	Bradley Pharmaceuticals, Inc.	Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
US6429231B1 (en) *	2001-09-24	2002-08-06	Bradley Pharmaceuticals, Inc.	Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use
JP2003327536A (ja) *	2002-03-07	2003-11-19	Kitasato Inst:The	ヒト免疫不全症候群ウイルスの感染、増殖抑制剤
US6858083B2 (en) *	2002-06-05	2005-02-22	Scimed Lifesystems, Inc.	Apparatus and method for closed-loop control of RF generator for welding polymeric catheter components
US20030017985A1 (en) *	2002-07-02	2003-01-23	Taylor Gregory Alan	Molecules that influence pathogen resistance
RU2255730C1 (ru) *	2003-10-14	2005-07-10	Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ")	Стабильная фармацевтическая суспензия азитромицина и способ ее получения
DE102004055316A1 (de) *	2004-11-16	2006-05-18	Bayer Healthcare Ag	Verhinderung vertikaler Endoparasiten-Infektionen
TW201233389A (en)	2005-10-05	2012-08-16	Otsuka Pharma Co Ltd	Antituberculous therapeutic drugs and kit containing the same
US7799885B2 (en)	2005-11-30	2010-09-21	Corning Incorporated	Photo or electron beam curable compositions
US20090054380A1 (en) *	2005-12-20	2009-02-26	Greenstein Robert J	Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection
SG170028A1 (en) *	2006-02-24	2011-04-29	Callida Genomics Inc	High throughput genome sequencing on dna arrays
RU2320337C1 (ru) *	2006-06-09	2008-03-27	Федеральное государственное унитарное предприятие "Государственный научный центр по антибиотикам"	Способ получения антимикробной композиции с рифабутином
FR2944014A1 (fr)	2009-04-06	2010-10-08	Univ Grenoble 1	Peptides cycliques a activite antiparasitaire
CN114601840A (zh) *	2020-12-08	2022-06-10	复旦大学附属中山医院	一种联合用药,用于治疗卡氏肺孢子虫肺炎
CN113230248A (zh) *	2021-06-18	2021-08-10	宁波大学	利卡灵-b及其组合物在制备治疗或预防弓形虫病药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3644616A (en) *	1969-03-24	1972-02-22	Ciba Geigy Corp	Synergistic composition of rifampicin and streptomycin
US4054663A (en) *	1974-12-23	1977-10-18	Sankyo Company Limited	Pyridine derivatives and their use as anticoccidial agents
US4094982A (en) *	1975-05-15	1978-06-13	Sankyo Company Limited	Pyridine sulfonamides and their use as anticoccidial agents
IT1056272B (it) *	1975-06-13	1982-01-30	Archifar Ind Chim Trentino	Prodotti derivati dalle amine aromatiche
IT1135270B (it) *	1980-04-12	1986-08-20	Erba Farmitalia	3-amidino-ansamicine
US5175319A (en) *	1983-04-14	1992-12-29	Burroughs Wellcome Co.	Naphthoquinone derivatives
US5053432A (en) *	1983-04-14	1991-10-01	Burroughs Wellcome Co.	Naphthoquinone derivatives
DE3512194A1 (de) *	1985-04-03	1986-10-09	Hoechst Ag, 6230 Frankfurt	Ein neues ansamycin-antibiotikum, ein mikrobielles verfahren zu seiner herstellung und seine verwendung als arzneimittel
WO1989002271A1 (en) *	1987-09-10	1989-03-23	Pfizer	Azithromycin and derivatives as antiprotozoal agents
GB9000241D0 (en) *	1990-01-05	1990-03-07	Coopers Animal Health	Pharmaceutical use
US5529994A (en) *	1993-05-05	1996-06-25	Palo Alto Medical Foundation	Treatment for toxoplasmosis

1994
- 1994-04-29 DE DE69400631T patent/DE69400631T2/de not_active Expired - Fee Related
- 1994-04-29 AU AU69050/94A patent/AU669300B2/en not_active Ceased
- 1994-04-29 ES ES94917283T patent/ES2095772T3/es not_active Expired - Lifetime
- 1994-04-29 DK DK94917283.7T patent/DK0648121T3/da active
- 1994-04-29 CA CA002138643A patent/CA2138643A1/en not_active Abandoned
- 1994-04-29 JP JP6524580A patent/JPH07509003A/ja active Pending
- 1994-04-29 AT AT94917283T patent/ATE143601T1/de not_active IP Right Cessation
- 1994-04-29 WO PCT/US1994/004765 patent/WO1994025038A1/en not_active Ceased
- 1994-04-29 EP EP94917283A patent/EP0648121B1/de not_active Expired - Lifetime
- 1994-04-29 RU RU95105973A patent/RU2121838C1/ru active
- 1994-05-04 IL IL109543A patent/IL109543A/en not_active IP Right Cessation
1995
- 1995-01-04 NO NO950030A patent/NO950030L/no unknown
- 1995-06-07 US US08/476,508 patent/US5670496A/en not_active Expired - Fee Related
- 1995-06-07 US US08/481,689 patent/US5641769A/en not_active Expired - Fee Related
- 1995-06-07 US US08/487,721 patent/US5665707A/en not_active Expired - Fee Related
- 1995-06-07 US US08/474,998 patent/US5648345A/en not_active Expired - Fee Related
- 1995-06-07 US US08/481,741 patent/US5650405A/en not_active Expired - Fee Related
1996
- 1996-11-28 GR GR960403219T patent/GR3021828T3/el unknown

Also Published As

Publication number	Publication date
IL109543A (en)	1998-06-15
EP0648121A1 (de)	1995-04-19
US5650405A (en)	1997-07-22
IL109543A0 (en)	1994-08-26
WO1994025038A1 (en)	1994-11-10
EP0648121B1 (de)	1996-10-02
US5648345A (en)	1997-07-15
DE69400631T2 (de)	1997-02-27
ATE143601T1 (de)	1996-10-15
RU2121838C1 (ru)	1998-11-20
NO950030D0 (no)	1995-01-04
AU6905094A (en)	1994-11-21
US5641769A (en)	1997-06-24
AU669300B2 (en)	1996-05-30
US5665707A (en)	1997-09-09
DK0648121T3 (de)	1997-02-24
ES2095772T3 (es)	1997-02-16
RU95105973A (ru)	1997-01-20
CA2138643A1 (en)	1994-11-10
DE69400631D1 (de)	1996-11-07
GR3021828T3 (en)	1997-02-28
US5670496A (en)	1997-09-23
JPH07509003A (ja)	1995-10-05

Publication	Publication Date	Title
NO950030D0 (no)	1995-01-04	Anvendelse av Rifamycin-derivater for fremstilling av et medikament for behandling av toxoplasmose
AU653415B2 (en)	1994-09-29	Method of treating ocular inflammation
LU91037I2 (fr)	2003-10-22	Somatulina autogel
LU91205I2 (fr)	2006-05-30	Ciclesonide et ses dérivés pharmaceutiquement acceptables (alvesco)
ATE133861T1 (de)	1996-02-15	Antihypertensive zubereitungen und deren verwendung
KR900701282A (ko)	1990-12-01	심장 또는 뇌의 허혈성 질환의 치료, 예방제
FR2630328B1 (fr)	1990-08-24	Derive de l'histamine, sa preparation et son application en therapeutique
HUP9802087A2 (hu)	1998-12-28	Eljárás mánia és bipoláris rendellenesség kezelésére alkalmas gyógyászati készítmények előállítására
EP0361645A3 (de)	1991-02-20	Organische Hydrazin-Verbindungen für pharmazeutische Anwendung
IE46171L (en)	1978-01-19	N-pyrrolidinylmethylbenzamide derivative.
FI884960A0 (fi)	1988-10-27	Anvaendning av 2-pyrimidinyl-1-piperazin-derivat.
DE69200365D1 (de)	1994-10-06	Pharmazeutische Zusammensetzung zur Verbesserung von Dysuria.
KR880004810A (ko)	1988-06-27	소화성 궤양 치료제
SE8804640D0 (sv)	1988-12-23	Medicament comprising cyclolinopeptide a
KR920003972A (ko)	1992-03-27	프로스타시클린 화합물을 이용한 백내장 치료
FI892685A0 (fi)	1989-06-01	Menetelmä uusien, sytostaattisesti vaikuttavien antrasykliinijohdannaisten valmistamiseksi
KR900016130A (ko)	1990-11-12	2-피리딜메틸티오 유도체 및 궤양 치료제
EP0260790A3 (de)	1992-01-22	Verwendung von Pinacidil zur Behandlung von Inkontinenz
DK0728002T3 (da)	2002-04-08	Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 7-infektioner
NZ336249A (en)	2000-11-24	parenteral composition of a dihydropolyprenol and a pharmaceutically acceptable oil
WO2001005384A3 (en)	2001-05-25	Manumycin derivatives for treating parasitic disorders
FR2699919B1 (fr)	1995-01-27	Dérivés d'imidazole, leur procédé de préparation et leur application en thérapeutique.
KR940002268A (ko)	1994-02-17	21-클로로-프레그난 유도체
GB9323403D0 (en)	1994-01-05	Pharmaceuticals
FR2693194B1 (fr)	1994-09-23	Dérivés d'alcanecarboxamide, leur préparation et leur application thérapeutique.